Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Other financing activities (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 4 years of Other financing activities data on record, last reported at $1.4 million in Q1 2025.

  • For Q1 2025, Other financing activities fell 42.18% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 178.04%, while the annual FY2025 figure was $1.4 million, 178.04% up from the prior year.
  • Other financing activities reached $1.4 million in Q1 2025 per MRVI's latest filing, up from -$8.8 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.4 million in Q1 2024 and bottomed at -$8.8 million in Q4 2024.
  • Average Other financing activities over 3 years is $642333.3, with a median of $2.0 million recorded in 2023.
  • The widest YoY moves for Other financing activities: up 383.33% in 2024, down 479.85% in 2024.
  • A 3-year view of Other financing activities shows it stood at $2.3 million in 2023, then tumbled by 479.85% to -$8.8 million in 2024, then soared by 115.58% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $1.4 million in Q1 2025, -$8.8 million in Q4 2024, and $2.3 million in Q3 2024.